<p>Cystic fibrosis, an autosomal recessive disease, causes premature mortality with a current life expectancy of 56 years.<span><sup>1</sup></span> Variations in a single gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), an anion channel, cause this multisystemic disease.<span><sup>2</sup></span> Bronchiectasis remains the most significant contributor to mortality, with other affected systems including the gastrointestinal, pancreatic, hepatobiliary, sweat glands and reproductive systems.<span><sup>3</sup></span> Clinical manifestations of cystic fibrosis vary widely, leading to diverse phenotypic expressions.</p><p>Over 2000 <i>CFTR</i> variants have been described worldwide, with 719 confirmed as disease causing.<span><sup>4</sup></span> These pathogenic variants are classified based on their functional consequence on the CFTR protein<span><sup>2</sup></span> (Box 1). Class II includes F508del, the most prevalent <i>CFTR</i> variant globally.<span><sup>2</sup></span> In Australia, about 90% of people with cystic fibrosis have at least one copy and about 50% are homozygous for the F508del allele.<span><sup>2, 5</sup></span></p><p>Therapeutic management of cystic fibrosis has evolved significantly over the past century. Aggressive early intervention with optimised nutrition, airway clearance and antibiotics, along with newborn screening and the introduction of specialist centres, increased the life expectancy from 4 to 40 years, but with a significant burden of care impacting quality of life.<span><sup>3</sup></span> A landmark development occurred in 2011, 22 years after the <i>CFTR</i> gene was isolated, with the introduction of the first targeted disease modifying therapy, ivacaftor.<span><sup>2</sup></span></p><p>Four CFTR modulators (ivacaftor, lumacaftor, tezacaftor and elexacaftor) have received approval from major regulatory bodies (Box 2). These approvals followed a development strategy with high throughput screening of 228 000 compounds, using Fischer rat thyroid (FRT) cell lines and human bronchial epithelial cells.<span><sup>2</sup></span> Drug candidates underwent animal toxicity studies and human clinical trials to ensure safety and efficacy. Ivacaftor functions as a CFTR channel potentiator.<span><sup>2</sup></span> Lumacaftor and tezacaftor, first-generation correctors, stabilise the CFTR protein to prevent premature degradation in the endoplasmic reticulum and are currently approved as dual combination medications with ivacaftor.<span><sup>2</sup></span> The latest advancement is the triple combination therapy of two correctors, elexacaftor and tezacaftor, with ivacaftor (ETI), which is approved for people with cystic fibrosis with at least one <i>F508del-CFTR</i> allele.<span><sup>6</sup></span></p><p>The rarity of certain <i>CFTR</i> variants presents a challenge to large scale phase 3 clinical trials. To address this, in vitro data from FRT cell experiments were submitted to the American Food and Dr
{"title":"The equitable challenges to quality use of modulators for cystic fibrosis in Australia","authors":"Laura K Fawcett, Shafagh A Waters, Adam Jaffe","doi":"10.5694/mja2.52527","DOIUrl":"10.5694/mja2.52527","url":null,"abstract":"<p>Cystic fibrosis, an autosomal recessive disease, causes premature mortality with a current life expectancy of 56 years.<span><sup>1</sup></span> Variations in a single gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), an anion channel, cause this multisystemic disease.<span><sup>2</sup></span> Bronchiectasis remains the most significant contributor to mortality, with other affected systems including the gastrointestinal, pancreatic, hepatobiliary, sweat glands and reproductive systems.<span><sup>3</sup></span> Clinical manifestations of cystic fibrosis vary widely, leading to diverse phenotypic expressions.</p><p>Over 2000 <i>CFTR</i> variants have been described worldwide, with 719 confirmed as disease causing.<span><sup>4</sup></span> These pathogenic variants are classified based on their functional consequence on the CFTR protein<span><sup>2</sup></span> (Box 1). Class II includes F508del, the most prevalent <i>CFTR</i> variant globally.<span><sup>2</sup></span> In Australia, about 90% of people with cystic fibrosis have at least one copy and about 50% are homozygous for the F508del allele.<span><sup>2, 5</sup></span></p><p>Therapeutic management of cystic fibrosis has evolved significantly over the past century. Aggressive early intervention with optimised nutrition, airway clearance and antibiotics, along with newborn screening and the introduction of specialist centres, increased the life expectancy from 4 to 40 years, but with a significant burden of care impacting quality of life.<span><sup>3</sup></span> A landmark development occurred in 2011, 22 years after the <i>CFTR</i> gene was isolated, with the introduction of the first targeted disease modifying therapy, ivacaftor.<span><sup>2</sup></span></p><p>Four CFTR modulators (ivacaftor, lumacaftor, tezacaftor and elexacaftor) have received approval from major regulatory bodies (Box 2). These approvals followed a development strategy with high throughput screening of 228 000 compounds, using Fischer rat thyroid (FRT) cell lines and human bronchial epithelial cells.<span><sup>2</sup></span> Drug candidates underwent animal toxicity studies and human clinical trials to ensure safety and efficacy. Ivacaftor functions as a CFTR channel potentiator.<span><sup>2</sup></span> Lumacaftor and tezacaftor, first-generation correctors, stabilise the CFTR protein to prevent premature degradation in the endoplasmic reticulum and are currently approved as dual combination medications with ivacaftor.<span><sup>2</sup></span> The latest advancement is the triple combination therapy of two correctors, elexacaftor and tezacaftor, with ivacaftor (ETI), which is approved for people with cystic fibrosis with at least one <i>F508del-CFTR</i> allele.<span><sup>6</sup></span></p><p>The rarity of certain <i>CFTR</i> variants presents a challenge to large scale phase 3 clinical trials. To address this, in vitro data from FRT cell experiments were submitted to the American Food and Dr","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"222 1","pages":"4-9"},"PeriodicalIF":6.7,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52527","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p>Participation is widely recognised as a determinant of children and young people's health.<span><sup>1</sup></span> Both the United Nations Declaration on the Rights of Indigenous Peoples (UNDRIP) (Article 18) and the Convention on the Rights of the Child (Article 12) enshrine participation as an inalienable right.<span><sup>2, 3</sup></span> Despite this, the exclusion and non-participation of Indigenous children, adolescents and young people persists.<span><sup>4</sup></span></p><p>Indigenous children and young people experience worse health outcomes than their non-Indigenous peers and are starkly over-represented in the contact with youth justice and in out-of-home care.<span><sup>5-7</sup></span> We propose this is in part due to their exclusion and non-participation — both as children and as Indigenous people.<span><sup>4, 5, 7</sup></span> These children and young people's stories are often told for them, if at all.<span><sup>4</sup></span> “It didn't matter what I screamed at (Child Protection Services), they wanted to tell my story for me, decide for me, know what was best for me. That's easier than listening, isn't it?”, said one Indigenous young person in contact with the youth justice system.<span><sup>6</sup></span></p><p>Indigenous young people are less likely to access primary health services despite having more health needs than non-Indigenous counterparts.<span><sup>8</sup></span> Most children and young people in the youth justice system have severe neurodevelopmental disorders — nearly all previously undiagnosed and untreated.<span><sup>9</sup></span> Current mainstream health and youth services are failing to provide culturally safe rudimentary services and meet Indigenous children and young people's unique needs.<span><sup>5, 7, 8, 10</sup></span> They have not been designed with meaningful participation of Indigenous people, let alone children and young people.<span><sup>5, 8</sup></span> There is an urgency for meaningful participation of Indigenous children and young people in reform.<span><sup>4, 7, 8</sup></span> There is an urgency for decision makers to listen and act.<span><sup>4, 5, 7, 8</sup></span></p><p>Best-practice mechanisms like the case study provided in this article, the Victorian based youth-led, Indigenous-led Koorie Youth Council, which centres self-determination, can ensure that Indigenous children and young people are empowered.<span><sup>4</sup></span> This article is part of the 2024 <i>MJA</i> supplement for the Future Healthy Countdown 2030, which examines how participating affects the health and wellbeing of children, young people and future generations. Society must not only uphold Indigenous children and young people's rights, but also value their strengths and the expertise they hold about their own lives.<span><sup>4, 5, 7, 8, 11</sup></span></p><p>Participation is not a binary, it exists on a spectrum indicating the degree of agency afforded to individuals or groups to relationally determine
{"title":"Participation of Indigenous children and young people to improve health and wellbeing","authors":"Jordan Cory (Kamilaroi), Hope Kuchel (Barkindji), Bonnie Dukakis (Gunditjmara), Rhian Dicker (Palawa), Sandra Eades (Noongar)","doi":"10.5694/mja2.52490","DOIUrl":"10.5694/mja2.52490","url":null,"abstract":"<p>Participation is widely recognised as a determinant of children and young people's health.<span><sup>1</sup></span> Both the United Nations Declaration on the Rights of Indigenous Peoples (UNDRIP) (Article 18) and the Convention on the Rights of the Child (Article 12) enshrine participation as an inalienable right.<span><sup>2, 3</sup></span> Despite this, the exclusion and non-participation of Indigenous children, adolescents and young people persists.<span><sup>4</sup></span></p><p>Indigenous children and young people experience worse health outcomes than their non-Indigenous peers and are starkly over-represented in the contact with youth justice and in out-of-home care.<span><sup>5-7</sup></span> We propose this is in part due to their exclusion and non-participation — both as children and as Indigenous people.<span><sup>4, 5, 7</sup></span> These children and young people's stories are often told for them, if at all.<span><sup>4</sup></span> “It didn't matter what I screamed at (Child Protection Services), they wanted to tell my story for me, decide for me, know what was best for me. That's easier than listening, isn't it?”, said one Indigenous young person in contact with the youth justice system.<span><sup>6</sup></span></p><p>Indigenous young people are less likely to access primary health services despite having more health needs than non-Indigenous counterparts.<span><sup>8</sup></span> Most children and young people in the youth justice system have severe neurodevelopmental disorders — nearly all previously undiagnosed and untreated.<span><sup>9</sup></span> Current mainstream health and youth services are failing to provide culturally safe rudimentary services and meet Indigenous children and young people's unique needs.<span><sup>5, 7, 8, 10</sup></span> They have not been designed with meaningful participation of Indigenous people, let alone children and young people.<span><sup>5, 8</sup></span> There is an urgency for meaningful participation of Indigenous children and young people in reform.<span><sup>4, 7, 8</sup></span> There is an urgency for decision makers to listen and act.<span><sup>4, 5, 7, 8</sup></span></p><p>Best-practice mechanisms like the case study provided in this article, the Victorian based youth-led, Indigenous-led Koorie Youth Council, which centres self-determination, can ensure that Indigenous children and young people are empowered.<span><sup>4</sup></span> This article is part of the 2024 <i>MJA</i> supplement for the Future Healthy Countdown 2030, which examines how participating affects the health and wellbeing of children, young people and future generations. Society must not only uphold Indigenous children and young people's rights, but also value their strengths and the expertise they hold about their own lives.<span><sup>4, 5, 7, 8, 11</sup></span></p><p>Participation is not a binary, it exists on a spectrum indicating the degree of agency afforded to individuals or groups to relationally determine","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 S10","pages":"S26-S33"},"PeriodicalIF":6.7,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52490","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Muideen T Olaiya, Joosup Kim, Christopher Pearce, Kiran Bam, Dominique A Cadilhac, Nadine E Andrew, Lauren M Sanders, Amanda G Thrift, Mark R Nelson, Seana Gall, Monique F Kilkenny